Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancer.
Journal: medRxiv : the preprint server for health sciences
Published: June 04, 2026
APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.
Journal: ESMO open
Published: February 26, 2026
A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.
Journal: Cancer research communications
Published: February 20, 2026
The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.
Journal: Cells
Published: December 01, 2025
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.
Journal: ESMO open
Published: August 21, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.
Journal: Cell genomics
Published: December 03, 2024
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.
Journal: ESMO open
Published: July 26, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Journal: ESMO open
Published: March 04, 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 09, 2024
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future.
Journal: ESMO gastrointestinal oncology
Published: February 01, 2024
Last Updated: 09/26/2026